Spelling suggestions: "subject:"able.""
41 |
Expressão de microRNAs em células Bcr-Abl1 positivas: associação com a resistência à apoptose e fisiopatologia da Leucemia Mielóide Crônica / MicroRNA expression in Bcr-Abl1 positive cells: association with apoptosis resistance and Chronic Myeloid Leukemia physiopathologyFerreira, Aline Fernanda 25 May 2012 (has links)
A leucemia mielóide crônica (LMC) é uma doença mieloproliferativa resultante da expansão clonal da célula hematopoética precursora. Sua fisiopatologia está associada ao cromossomo (cr) Philadelphia (Ph) originado da t(9;22) e ao oncogene bcr-abl1 que codifica a proteína Bcr-Abl1 com constitutiva atividade de tirosinoquinase (TK). A expressão de Bcr-Abl determina a leucemogênese por meio da alteração da adesão das células progenitoras leucêmicas ao estroma medular e resistência à apoptose. Os inibidores de TK, o mesilato de imatinibe, dasatinibe e nilotinibe são utilizados no tratamento da LMC, entretanto, casos de resistência têm sido relacionados à presença de mutações em Bcr-Abl1, duplicação do cr Ph e superexpressão do gene bcr-abl1. A resistência ou refratariedade de alguns pacientes ao tratamento com inibidores de TK impulsiona a realização de estudos para melhor conhecimento da fisiopatologia da LMC e descrição de novos alvos terapêuticos. Nesse contexto, o presente estudo investigou a participação de microRNAs na modulação da expressão de genes que regulam a apoptose. O objetivo geral deste trabalho foi investigar o efeito de bcr-abl1 e da atividade tirosinoquinase de Bcr-abl na expressão desses miRNAs em linhagens celulares e pacientes com LMC. O RNA das linhagens celulares, de pacientes e controles foram obtidos por meio da extração com Trizol® e o cDNA sintetizado com o kit High Capacity cDNA reverse transcription. A expressão dos microRNAs e dos genes alvoss foi quantificada por PCR em tempo real utilizando o kit SYBR Green PCR Master Mix® e TaqMan Universal PCR Master Mix®. A inibição de Bcr-Abl1 na linhagem HL-60.Bcr-Abl1 tratada com o mesilato de imatinibe aumentou a expressão de miR-let-7d, miR-15a, miR-130a e miR-145 e diminuiu os níveis de miR-21. O tratamento com dasatinibe aumentou a expressão de miR-let-7e, miR-15a, miR-16, miR-21, miR-30e, miR-130a e miR-142-3p. O nilotinibe aumentou a expressão de miR-let-7e, miR-15a, miR-16, miR-130a e miR-145 e, diminuiu os níveis de miRlet- 7d e miR-21. Os resultados obtidos da análise entre os de pacientes com LMC em diferentes fases da doença mostraram elevados níveis de miR-15a, miR-130b e miR-145 em pacientes na fase crônica versus controles e baixos níveis de miR-16, miR-26a e miR-146a. Pacientes em fases avançadas versus controles apresentaram baixa expressão de miR-let-7d, miR-16, miR-142-3p, miR-145 e miR-146a. Baixos níveis de miR-let-7d, miR-15a, miR-16, miR-29c, miR-142-3p, miR-145 e miR-146a foram observados nas fases avançadas da LMC em relação a fase crônica. Os genes anti-apoptóticos a1, bcl-2, c-flip, ciap-1 e ciap-2 estavam mais elevados na fase crônica do que nos controles. A expressão do gene c-flip estava diminuída e dos genes a1, ciap-1 e mcl-1 aumentada nas fases avançadas em relação aos controles e a fase crônica. Pacientes com LMC resistentes ao MI apresentaram menores níveis de miR-26a, miR-29c, miR-130b, miR-146a e dos genes anti-apoptóticos ciap-1 e mcl-1. Os dados obtidos sugerem que a TK Bcr-Abl modula a expressão de microRNAs que possuem como alvos genes que regulam a apoptose celular / Chronic myeloid leukemia (CML) is a myeloproliferative disease resulting from clonal expasion of hematopoietic precursor cells. Its physiopathology is associated to Philadelphia (Ph) chromosome (cr) originated from the t(9;22) and bcr-abl1 oncogene that encodes the Bcr-Abl protein with constitutive tyrosine kinase activity (TK). The Bcr-Abl1 expression determines leukemogenesis by altering the leukemic progenitor cells´ adhesion by bone marrow stroma and apoptosis resistance. TK inhibitors imatinib mesylate, dasatinib and nilotinib are used to treat CML, however, cases of resistance have been linked to mutation in Bcr-Abl1, duplication of the cr Ph and overexpression of the bcr-abl1. The resistance or refractoriness of some patients to treatment with TK inhibitors drives the studies to better understand the CML physiopathology and description of new therapeutic targets. In this context, this study investigated the participation of microRNAs in modulating expression of the genes that regulate apoptosis. The aim of this study was to investigate the effect of Bcr- Abl1 and its kinase activity in the expression of miRNAs in cell lines and CML patients. The RNA from cell lines, patients and controls were obtained by extraction with Trizol® and cDNA was synthesized with the kit High Capacity cDNA reverse transcription. The expression of miRNAs and target genes was quantified by real time PCR using SYBR Green PCR Master Mix® kit and TaqMan Universal PCR Master Mix®. The Bcr-Abl1 inhibition in the cell line HL-60.Bcr-Abl1 treated with imatinib mesylate increased the expression of miR-let- 7d, miR-15a, miR-130a and miR-145 and decreased miR-21 levels. Treatment with dasatinib increased the expression of miR-let-7e, miR-15a, miR-16, miR-21, miR-30e, miR-130a and miR- 142-3p. Nilotinib increased the expression of miR-let-7e, miR-15a, miR-16, miR-130a and miR- 145 and, decreased miR-let-7d and miR-21 levels. The results of the analysis among patients with CML in different stages of disease showed high levels of miR-15a, miR-130b and miR-145 in chronic phase versus controls and low levels of miR-16, miR-26a and miR-146a. Patients in advanced phases versus controls showed low expression of miR-let-7d, miR-16, miR-142-3p, miR-145 and miR-146a. Low levels of miR-let-7d, miR-15a, miR-16, miR-29c, miR-142-3p, miR-145 and miR-146a were observed in CML advanced phases when compared with chronic phase. The antiapoptotic genes a1, bcl-2, c-flip, ciap-1 and ciap-2 were higher in chronic phase than in controls. The c-flip expression was decreased and a1, ciap-1 and mcl-1 expression was increased in advanced phases when compared to controls and chronic phase. CML patients resistant to imatinib mesylate presented low levels of miR-26a, miR-29c, miR-130b, miR-146a and ciap-1 and mcl-1 antiapoptotic genes. The data obtained suggest that Bcr-Abl1 TK modulates the miRNA expression which has target genes involved in the apoptosis´ regulation.
|
42 |
Signalisation des GTPases de la famille Rho dans les phénotypes migratoires induits par les différentes formes de Bcr-Abl / Road marking of the GTPases of the family Rho in the migratory phenotypes led by the various forms of Bcr-AblRochelle, Tristan 05 July 2012 (has links)
Les oncogènes Bcr-Abl (p190bcr-abl et p210bcr-abl) sont issus d'une translocation chromosomique t(9,22) qui fusionne en phase les gènes bcr et c-abl. p210bcr-abl est généralement responsable de la Leucémie Myéloïde Chronique (LMC) alors que p190bcr-abl induit un sous type de Leucémie Aigue Lymphoblastique (LAL). La seule différence structurale entre ces deux protéines est la présence d'un domaine DH/PH au sein de p210bcr-abl activateur spécifique de RhoA. L'expression de Bcr-Abl dans la lignée Ba/F3 est associée au déclenchement d'une migration spontanée, dépourvue de directionnalité, sous la dépendance de la GTPase Rac1.L'activation de RhoA, spécifique des cellules Ba/F3p210, est associée à un phénotype migratoire amœboïde dans une matrice de Matrigel™ en 3D où les cellules Ba/F3p190 dépourvues de RhoA activé, présentent une mobilité de type roulement. Dans ce travail, nous avons mis en évidence que l'activation spécifique de ROCK1 par RhoA détermine deux voies parallèles et mutuellement indispensables pour le mouvement amœboïde : 1) la voie de la Chaine Légère de Myosine (CLM) 2) celle des protéines de la famille ADF (Actin Depolymerizing Factor), et plus particulièrement l'isoforme ADF/destrine. Nous démontrons également l'existence d'invadopodes spécifiquement dans les cellules Ba/F3p190, dont la formation est sous la dépendance de l'absence d'activation de RhoA corrélée à une augmentation de l'activation de Cdc42. Enfin nous démontrons que la voie de signalisation RhoA/ROCK est spécifiquement activée dans les progéniteurs hématopoïétiques CD34+ issus de patients atteints de LMC et ce, indépendamment de l'activité tyrosine kinase de Bcr-Abl. / Bcr-Abl chimeric oncogenes (p190bcr-abl and p210bcr-abl) result from the t(9,22) chromosomal translocation that fuse the bcr and the c-abl genes. p210bcr-abl and p190bcr-abl are associated with Chronic Myelogenous Leukemia (CML) and a subset of Acute Lymphoblastic Leukemia (ALL) respectively. The only difference between these two chimeras is the presence of a specific RhoA-GEF domain in the p210bcr-abl oncogene. Bcr-Abl expression in Ba/F3 lymphoblasts induces spontaneous migration of these cells without apparent directionality. Motility triggering of Bcr-Abl-expressing Ba/F3 depends on the RhoGTPase Rac1.RhoA activity is associated with a typical amoeboid movement of Ba/F3p210 cells embedded in Matrigel™ 3D matrix, whereas the Ba/F3p190 cells, devoid of RhoA activity, display a rolling-type motility. In this work we showed that activation of the RhoA effector ROCK1 triggers two parallel pathways which are both necessary for amoeboid movement: 1) the Myosin Light chain (MLC) pathway 2) ADF family proteins (Actin Depolymerizing Factor) pathway, specifically the ADF/destrin isoform. Besides, we showed that Ba/F3p190 cells could assemble invadopodia-like structures. The formation of these structures is driven by the reduction of RhoA activity associated with the absence of the DH/PH domain in p190bcr-abl and correlates with an increase in Cdc42 activity. We finally demonstrated that the RhoA/ROCK pathway is constitutively activated in CD34+ cells isolated from CML patients while not in their normal counterparts. We also demonstrated that this activation is independent of the tyrosine Kinase activity of Bcr-Abl.
|
43 |
Expressão de microRNAs em células Bcr-Abl1 positivas: associação com a resistência à apoptose e fisiopatologia da Leucemia Mielóide Crônica / MicroRNA expression in Bcr-Abl1 positive cells: association with apoptosis resistance and Chronic Myeloid Leukemia physiopathologyAline Fernanda Ferreira 25 May 2012 (has links)
A leucemia mielóide crônica (LMC) é uma doença mieloproliferativa resultante da expansão clonal da célula hematopoética precursora. Sua fisiopatologia está associada ao cromossomo (cr) Philadelphia (Ph) originado da t(9;22) e ao oncogene bcr-abl1 que codifica a proteína Bcr-Abl1 com constitutiva atividade de tirosinoquinase (TK). A expressão de Bcr-Abl determina a leucemogênese por meio da alteração da adesão das células progenitoras leucêmicas ao estroma medular e resistência à apoptose. Os inibidores de TK, o mesilato de imatinibe, dasatinibe e nilotinibe são utilizados no tratamento da LMC, entretanto, casos de resistência têm sido relacionados à presença de mutações em Bcr-Abl1, duplicação do cr Ph e superexpressão do gene bcr-abl1. A resistência ou refratariedade de alguns pacientes ao tratamento com inibidores de TK impulsiona a realização de estudos para melhor conhecimento da fisiopatologia da LMC e descrição de novos alvos terapêuticos. Nesse contexto, o presente estudo investigou a participação de microRNAs na modulação da expressão de genes que regulam a apoptose. O objetivo geral deste trabalho foi investigar o efeito de bcr-abl1 e da atividade tirosinoquinase de Bcr-abl na expressão desses miRNAs em linhagens celulares e pacientes com LMC. O RNA das linhagens celulares, de pacientes e controles foram obtidos por meio da extração com Trizol® e o cDNA sintetizado com o kit High Capacity cDNA reverse transcription. A expressão dos microRNAs e dos genes alvoss foi quantificada por PCR em tempo real utilizando o kit SYBR Green PCR Master Mix® e TaqMan Universal PCR Master Mix®. A inibição de Bcr-Abl1 na linhagem HL-60.Bcr-Abl1 tratada com o mesilato de imatinibe aumentou a expressão de miR-let-7d, miR-15a, miR-130a e miR-145 e diminuiu os níveis de miR-21. O tratamento com dasatinibe aumentou a expressão de miR-let-7e, miR-15a, miR-16, miR-21, miR-30e, miR-130a e miR-142-3p. O nilotinibe aumentou a expressão de miR-let-7e, miR-15a, miR-16, miR-130a e miR-145 e, diminuiu os níveis de miRlet- 7d e miR-21. Os resultados obtidos da análise entre os de pacientes com LMC em diferentes fases da doença mostraram elevados níveis de miR-15a, miR-130b e miR-145 em pacientes na fase crônica versus controles e baixos níveis de miR-16, miR-26a e miR-146a. Pacientes em fases avançadas versus controles apresentaram baixa expressão de miR-let-7d, miR-16, miR-142-3p, miR-145 e miR-146a. Baixos níveis de miR-let-7d, miR-15a, miR-16, miR-29c, miR-142-3p, miR-145 e miR-146a foram observados nas fases avançadas da LMC em relação a fase crônica. Os genes anti-apoptóticos a1, bcl-2, c-flip, ciap-1 e ciap-2 estavam mais elevados na fase crônica do que nos controles. A expressão do gene c-flip estava diminuída e dos genes a1, ciap-1 e mcl-1 aumentada nas fases avançadas em relação aos controles e a fase crônica. Pacientes com LMC resistentes ao MI apresentaram menores níveis de miR-26a, miR-29c, miR-130b, miR-146a e dos genes anti-apoptóticos ciap-1 e mcl-1. Os dados obtidos sugerem que a TK Bcr-Abl modula a expressão de microRNAs que possuem como alvos genes que regulam a apoptose celular / Chronic myeloid leukemia (CML) is a myeloproliferative disease resulting from clonal expasion of hematopoietic precursor cells. Its physiopathology is associated to Philadelphia (Ph) chromosome (cr) originated from the t(9;22) and bcr-abl1 oncogene that encodes the Bcr-Abl protein with constitutive tyrosine kinase activity (TK). The Bcr-Abl1 expression determines leukemogenesis by altering the leukemic progenitor cells´ adhesion by bone marrow stroma and apoptosis resistance. TK inhibitors imatinib mesylate, dasatinib and nilotinib are used to treat CML, however, cases of resistance have been linked to mutation in Bcr-Abl1, duplication of the cr Ph and overexpression of the bcr-abl1. The resistance or refractoriness of some patients to treatment with TK inhibitors drives the studies to better understand the CML physiopathology and description of new therapeutic targets. In this context, this study investigated the participation of microRNAs in modulating expression of the genes that regulate apoptosis. The aim of this study was to investigate the effect of Bcr- Abl1 and its kinase activity in the expression of miRNAs in cell lines and CML patients. The RNA from cell lines, patients and controls were obtained by extraction with Trizol® and cDNA was synthesized with the kit High Capacity cDNA reverse transcription. The expression of miRNAs and target genes was quantified by real time PCR using SYBR Green PCR Master Mix® kit and TaqMan Universal PCR Master Mix®. The Bcr-Abl1 inhibition in the cell line HL-60.Bcr-Abl1 treated with imatinib mesylate increased the expression of miR-let- 7d, miR-15a, miR-130a and miR-145 and decreased miR-21 levels. Treatment with dasatinib increased the expression of miR-let-7e, miR-15a, miR-16, miR-21, miR-30e, miR-130a and miR- 142-3p. Nilotinib increased the expression of miR-let-7e, miR-15a, miR-16, miR-130a and miR- 145 and, decreased miR-let-7d and miR-21 levels. The results of the analysis among patients with CML in different stages of disease showed high levels of miR-15a, miR-130b and miR-145 in chronic phase versus controls and low levels of miR-16, miR-26a and miR-146a. Patients in advanced phases versus controls showed low expression of miR-let-7d, miR-16, miR-142-3p, miR-145 and miR-146a. Low levels of miR-let-7d, miR-15a, miR-16, miR-29c, miR-142-3p, miR-145 and miR-146a were observed in CML advanced phases when compared with chronic phase. The antiapoptotic genes a1, bcl-2, c-flip, ciap-1 and ciap-2 were higher in chronic phase than in controls. The c-flip expression was decreased and a1, ciap-1 and mcl-1 expression was increased in advanced phases when compared to controls and chronic phase. CML patients resistant to imatinib mesylate presented low levels of miR-26a, miR-29c, miR-130b, miR-146a and ciap-1 and mcl-1 antiapoptotic genes. The data obtained suggest that Bcr-Abl1 TK modulates the miRNA expression which has target genes involved in the apoptosis´ regulation.
|
44 |
Om indirekt- och "indirekt" indirekt skada : Enskilda aktieägares rätt till ersättning vid skadegörande handling av organledamot jämte genomsyn i koncernförhållanden / Indirect- and "indirect" indirect injury : An individual shareholders right to indemnity for damages caused by a corporate member next to piercing the corporate veil in a corporate groupWall, Anna January 2012 (has links)
I de fall enskilda aktieägare tillfogas skada, genom organledamots handlande, innehar dessa rättigheten att påkalla skadeståndsansvar enligt 29:1 1 st. 2 men. ABL. I den svenska rättstillämpningen ter sig dock tillämpningen av paragrafen, i samband med indirekta skador, problematisk. Problematiken hänför sig till vilka regler, vars åsidosättande, aktualiserar tillämpningen av paragrafen tillsammans med aktieägares talerätt. Två tolkningar kan i fallet identifieras, vilka framförts inom doktrinen, varvid en begränsad och en mer liberal. Även om den liberala tolkningen är förenad med viss problematik, är denna enligt mitt förmenande den vilken bör tillämpas. En sådan tillämpning skulle således innebära att enskilda aktieägare tillerkänns talerätt vid indirekt skada, då regler vilka ger uttryck för normskyddsläran och bolagsledningens lojalitetsplikt åsidosatts. Rättsutvecklingen har vidare givet upphov till frågan, huruvida en ”indirekt” indirekt skada kan omfattas av paragrafens tillämpningsområde. En sådan skada uppstår särskilt i koncernförhållanden då dotterbolaget tillfogas en direkt skada, vilken därigenom åsamkar aktieägarna i dess moderbolag en ”indirekt” indirekt skada. Skadan faller utanför paragrafens tillämpningsområde, då de skadedrabbade inte utgör aktieägare i dotterbolaget. En lösning enligt mitt förmenande, varigenom paragrafens tillämpning koncernanpassas, är att principen om ansvarsgenombrott i betydelsen genomsyn nyttjas. Principens aktualisering medför att ett moder- och dotterbolag betraktas som en juridisk enhet, om erforderliga rekvisit uppfylls, varigenom de skadedrabbade aktieägarna från ett teoretiskt perspektiv även ses som aktieägare i dotterbolaget. Effekten av principens tillämpning är sålunda att en ”indirekt” indirekt skada faller inom paragrafens tillämpningsområde. / Whenever individual shareholders inflict an injury, due to action taken by a corporate member, they possess the right to impose liability in accordance with 29:1 1 st. 2 men. ABL. The paragraph is though associated with some difficulties when it comes to an indirect injury. The difficulties regard which rules that have to be infringed, in order for the paragraph to be applicable and thereby providing shareholders with the right to sue. Two different interpretations can hereby be identified, whereby one limited and the other one more liberal. Even if the liberal interpretation is associated with some difficulties, I find that this one should be applied. Such an application would mean that an individual shareholder acquire the right to sue, for an indirect injury, when rules protecting a third person and the corporate member’s duty of loyalty have been infringed. Legal progress has also given rise to another question, whether an “indirect” indirect injury falls within the paragraphs application. Such an injury is mostly affiliated with corporate groups where the daughter company causes a direct injury, whereby the shareholders in the mother company causes an “indirect” indirect injury. Since the shareholder here is not an owner of the daughter company, the paragraph could not be applied. A solution to this problem is, according to me, an application of the principle piercing the corporate veil, whereby the paragraphs application extends to corporate groups. The effect of the principles application is that a mother- and daughter company becomes one legal entity, if the prerequisites are fulfilled. The outcome is hereby that a shareholder in the mother company, from a theoretical perspective, also is regarded to be an owner of the daughter company. Wherefore an “indirect” indirect injury hereby falls within the scope of the paragraphs application.
|
45 |
Förtäckt värdeöverföring och koncerninterna borgensåtaganden : Om förutsättningarna för att dotterbolags borgensåtagande för koncernbolags skuld ska anses utgöra förtäckt värdeöverföring enligt 17:1 första stycket 4 p. ABL. / (Disguised Distributions and intra-group guarantee commitments)Beling, Jonatan January 2024 (has links)
No description available.
|
46 |
Etude structurale et fonctionnelle d'un domaine intrinsèquement désordonné de l'oncoprotéine BCR-ABL responsable de la leucémie myéloïde chronique / Structural and functional study of an intrinsically disordered domain of the BCR-ABL oncoprotein responsible for chronic myeloid leukemiaManeville, Stephanie 09 October 2013 (has links)
L'oncoprotéine BCR-ABL est responsable de la physiopathologie de la Leucémie Myéloïde Chronique (LMC). La fusion d'une partie de la protéine ABL et de BCR entraîne une dérégulation de l'activité kinase portée par ABL. Plusieurs domaines contenus dans ces deux protéines jouent un rôle important dans l'activation du pouvoir oncogène. L'un d'entre eux est une région de BCR, située en N-terminal, contenant un domaine de liaison au domaine SH2. Durant ce travail de thèse, j'ai caractérisé, pour la première fois, les propriétés structurales de cette région, à l'aide de plusieurs méthodes biophysiques: le domaine de BCR est intrinsèquement désordonné. En parallèle, j'ai étudié les interactions entre le domaine de liaison de BCR et les domaines SH d'ABL. J'ai identifié de nouveaux sites d'interactions avec ABL sur BCR. Enfin, j'ai évalué l'impact fonctionnel des nouveaux sites d’interactions au sein de l'oncoprotéines BCR-ABL, dans un modèle cellulaire. Les résultats préliminaires montrent que deux nouveaux sites auraient un rôle dans le pouvoir oncogénique de BCR-ABL. Ces résultats offrent la possibilité de développer de nouveaux médicaments complémentaires aux existants, qui cibleraient une nouvelle région de BCR-ABL, ainsi pourraient lutter contre les résistances apparues chez les patients vis-à-vis des traitements actuels. / The BCR-ABL oncoprotein is responsible for the pathogenesis of chronic myelogenous leukemia (CML). The fusion of a part of ABL and BCR leads to deregulation of kinase activity of ABL. Several domains in these two proteins play an important role in the activation of oncogenic properties. One of them is a BCR region, located at the N- terminal part, containing a SH2 domain binding. In this thesis , I have characterized for the first time , the structural properties of this region, using several biophysical methods : the domain of BCR is intrinsically disordered. In parallel, I have studied the interactions between the binding domain of BCR and theSH domains of ABL. I identified new sites of interaction with ABL into BCR. Finally, I evaluated the functional impact of new sites of interaction within the BCR- ABL oncoprotein in a cellular model. Preliminary results show that two new sites have a role in the oncogenic properties of BCR- ABL. These results offer the possibility to develop new drugs complementary to existing , that target a new region of BCR- ABL and could fight against the resistance occurred in patients vis-a-vis current treatments.
|
47 |
Controle da expressão de TRAIL, OSM, FAIM e NIPA pelo oncogene bcr-abl. / bcr-abl regulation of TRAIL, OSM, FAIM and NIPA expression.Leroy, Janine Marie Gisele 03 July 2008 (has links)
A leucemia mielóide crônica (LMC) é uma doença mieloproliferativa e sua patogênese está associada à expressão de um neogene, bcr-abl, que codifica uma proteína tirosina quinase Bcr-Abl. Esse trabalho tem como objetivos o estudo dos mecanismos envolvidos na resistência à morte das células Bcr-Abl positivas e a identificação de alterações gênicas nessas células. Dados de expressão gênica global obtidos por \"microarray\" mostraram uma superexpressão nas células HL-60.Bcr-Abl com relação a HL-60 dos genes faim e nipa, que foi confirmada por qRT-PCR em diferentes linhagens celulares Bcr-Abl positivas. Já os genes de trail e osm, apresentaram uma diminuição significativa em HL-60.Bcr-Abl, que foi confirmada para trail, porém osm não teve seu resultado validado. A avaliação da expressão dos genes em células de pacientes portadores de LMC, em diferentes fases da doença também foi estudada. Com esses resultados, o presente estudo visa a melhor compreensão de como alterações na expressão desses genes contribuem na fisiopatologia da LMC. / Chronic myelogenous leukemia (CML) is a stem cell disease characterized by the presence of the Bcr-Abl oncoprotein, which is the cause of the malignant transformation and the extreme resistance to apoptosis displayed by CML patients. Our aim was to analyze the alteration in global gene expression in Bcr-Abl expressing cells. Data obtained from microarray analysis showed significant up-regulation of nipa and faim in HL60.Bcr-Abl and down-regulation of osm and trail. These results were further confirmed by Real-Time PCR to nipa, faim and trail, but not for osm expression in HL-60.Bcr-Abl cells. To evaluate the potential of some of the modified genes as therapeutic targets or prognostic markers for CML, we also analyzed the expression of these genes in samples from CML patients.
|
48 |
Aspectos moleculares da transformação celular induzida por Bcr-Abl. / Molecular aspects of Bcr-Abl-induced cell transformation.Silva, Ana Elisa Barreiros Bueno da 11 April 2008 (has links)
As leucemias cromossomo Ph-positivas estão intimamente associadas à expressão da tirosina-quinase Bcr-Abl. Esta oncoproteína promove independência de fatores de crescimento, alterações na adesão e inibição da apoptose por mecanismos ainda não totalmente elucidados. O objetivo desse estudo foi avaliar a contribuição da atividade quinase de Bcr-Abl para seu potencial anti-apoptótico e identificar alterações moleculares envolvidas na transformação celular induzida por essa proteína. Nossos resultados sugerem que a resistência à apoptose não depende da manutenção constante da atividade tirosina-quinase de Bcr-Abl, tampouco da presença de proteínas fosforiladas em tirosina. A comparação do proteoma de células HL-60.vetor e HL-60.Bcr-Abl revelou que a presença de Bcr-Abl causa alterações profundas no padrão de expressão protéica. As proteínas afetadas estão associadas a diversos processos celulares, como adesão, transdução de sinais, proliferação e morte celular. Esses achados devem contribuir para a identificação de novos marcadores de prognóstico e alvos terapêuticos. / Ph chromosome-positive leukemias are closely associated with the expression of Bcr-Abl tyrosine kinase. This oncoprotein promotes growth factor independence, alters cell adhesion and confers resistance to apoptosis by mechanisms that are not fully understood. The aim of this study was to evaluate the contribution of Bcr-Abl kinase activity for its antiapoptotic potential and identify molecular alterations involved in Bcr-Abl-induced cell malignant transformation. Our results suggest that Bcr-Abl is not required to be constantly active to maintain the resistance to apoptosis and pY-containing proteins may not be responsible for the antiapoptotic effect of Bcr-Abl. The comparison between the proteome of HL-60.vector and HL-60.Bcr-Abl cells revealed that the presence of Bcr-Abl alters the expression of a great variety of proteins. The affected molecules are associated with several cellular processes, including cell adhesion, signal transduction, proliferation and cell death. Our findings might help the identification of new prognostic markers and therapeutic targets.
|
49 |
Expressão de galectina-1 e -3 na leucemia mielóide crônica e sua contribuição para a progressão da doença. / Expression of galectin-1 and -3 in chronic myeloid leukemia and its contribution to disease progression.Castro, Monica Alexandra Yon 09 June 2009 (has links)
A galectina-1 (LGALS1) participa em diferentes etapas da neoplasia, mas sua função na leucemia mielóide crônica (LMC) é desconhecida. Neste trabalho, a expressão etópica de BCR-ABL selvagem, mas não de BCR-ABL quinase deficiente, em linhagens celulares hematopoéticas, resultou em aumento de LGALS1. O efeito foi revertido com a inibição da tirosina quinase pelo mesilato de imatinibe. Este resultado indicou que a galectina-1 é modulada pela atividade tirosina-quinase de BCR-ABL. Em pacientes com LMC, a maior expressão de LGALS1 foi correlacionada a altos níveis de BCR-ABL, progressão da doença e a um tempo de sobrevida menor. Adicionalmente, as células K562 com LGALS1 inibida por RNA de interferência exibiram crescimento mais lento do que as células K562 com LGALS1 intacta, em camundongos nude. Portanto, o pior prognóstico de pacientes com altos níveis de galectina-1 sugere um efeito cooperativo de galectina-1 na tumorigênese de BCR-ABL reforçando o conceito de que a galectina-1 é um forte candidato para intervenção terapêutica na LMC. / Galectin-1 (LGALS1) participates in different steps of neoplasia but its role in chronic myeloid leukemia (CML) is unknown. In this work, ectopic expression of wild-type but not kinase-deficient BCR-ABL in different hematopoietic cells resulted in LGALS1 upregulation. Tyrosine-kinase inhibition by imatinib mesylate reversed this effect. This result indicate that galectin-1 is modulated by tyrosine kinase activity. In CML patients, the elevated expression of LGALS1 was correlated with high BCR-ABL levels, disease progression and shorter survival time. Additionally, in nude mice, LGALS1-deficient K562 cells obtained by RNA interference were less efficient in tumor formation than control K562 cells. Therefore, the worst prognosis in patients bearing high LGALS1 levels suggests a cooperative role for galectin-1 in BCR-ABL-positive leukemia and support the concept that galectin-1 is a strong candidate for CML therapeutic intervention.
|
50 |
Efeito do veneno bruto e da L-aminoácido oxidase de Bothrops pirajai em células BCR-ABL positivas / Effect of Bothrops pirajai crude venom and L-amino acid oxidase in BCR-ABL positive cells.Burin, Sandra Mara 01 July 2011 (has links)
A leucemia mielóide crônica (LMC) é uma doença mieloproliferativa caracterizada citogeneticamente pela presença do cromossomo Philadelfia (Ph) e molecularmente pelo neogene bcr-abl1 que codifica a oncoproteína BCR-ABL com alta atividade de tirosina-quinase. A célula leucêmica BCR-ABL+ apresenta baixa adesão ao estroma medular, resistência à apoptose e potencial mitogênico exacerbado. A LMC possui curso evolutivo trifásico (fase crônica, acelerada e blástica) e seu tratamento pode ser realizado por meio de diferentes modalidades terapêuticas, destacando-se o mesilato de imatinibe (MI) que inibe a TK BCR-ABL induzindo altas taxas de remissão citogenética dos pacientes na fase crônica da doença. Apesar do MI ser eficiente, os pacientes na fase acelerada e blástica da doença são comumente refratários a essa terapia e na fase crônica há casos de resistência ao MI descritos. Nesse contexto, potenciais novos fármacos são investigados para melhorar a eficiência da terapia da LMC. Nesse estudo, investigamos o efeito do veneno bruto (VB) e da enzima L-amino-ácido-oxidase (LAAO) da Bothrops pirajai em desencadear apoptose em células BCR-ABL+. A apoptose das células HL-60 e HL-60.BCR-ABL foi quantificada pela detecção da percentagem de células com núcleos hipodiplóides pela da citometria de fluxo e confirmada pela observação da ativação das caspases 3, 8 e 9 por western-blot. Os resultados obtidos indicam que a LAAO é capaz de induzir apoptose em células HL-60 e HL-60.BCR-ABL por ativação das vias extrínseca e intrínseca. Além disso, foi verificado que a LAAO diminui a fosforilação de BCR-ABL em células HL-60.BCR-ABL e quando associada ao MI potencializou a inibição da atividade quinase de BCR-ABL. Os dados da presente investigação indicaram ainda que a LAAO é capaz de modular a expressão de bad, bak, bax, bid, bimel, fas,fasl, a1, bcl-2, bcl-xl, bcl-w e c-flip, genes reguladores da apoptose celular. Apesar do pouco conhecimento acerca do mecanismo de ação dessa toxina, os dados obtidos sugerem que a LAAO possui o potencial de estimular a apoptose nas linhagens HL-60 e HL-60.BCR-ABL e aumentar o efeito do inibidor da atividade quinase, MI, dados relevantes para estudos futuros associados a descrição de novos fármacos contra leucemia mielóide crônica. / Chronic myeloid leukemia (CML) is a myeloproliferative disorder cytogenetically characterized by the presence of Philadelphia chromosome (Ph) and molecularly by bcr-abl1 neogene that encodes the BCR-ABL oncoprotein with high tyrosine kinase (TK) activity. The leukemic cell BCR-ABL+ presents poor adhesion to bone marrow stroma, resistance to apoptosis and exacerbated mitogenic potential. The CML has a three-phase course (chronic, accelerated and blastic phase) and its treatment can be performed by different therapeutic modalities, especially the imatinib mesylate (IM) that inhibits the TK BCR-ABL inducing high rates of cytogenetic remission in chronic phase. Although MI is effective, patients in accelerated and blastic phases of the disease are often refractory to this therapy and there are also cases of resistance to MI described in chronic phase. In this context, potential new drugs are investigated to improve the efficiency of the therapy of CML. In this study, we investigated the effect of crude venom (CV) and of the enzyme L-amino acid oxidase (LAAO) from Bothrops pirajai in triggering apoptosis in BCR-ABL+. The apoptosis of HL-60 cells and HL-60. BCR-ABL was quantified by detecting the percentage of cells with hypodiploid nuclei by flow cytometry and confirmed by observation of the activation of caspases 3, 8 and 9 by Western blot. The results indicate that LAAO is able to induce apoptosis in HL-60 cells and HL-60. BCR-ABL by activation of the extrinsic and intrinsic pathways. Furthermore, it was found that LAAO decreases phosphorylation of BCR-ABL in HL-60 cells. BCR-ABL when associated with MI potencialized the inhibition of kinase activity of BCR-ABL. The data from this study also indicated that the LAAO is able to modulate the expression of bad, bak, bax, bid, bimel, fas, FasL, A1, bcl-2, bcl-xl, bcl-w and c-flip, regulatory genes of apoptosis. Even though there is little knowledge about the mechanism of action of this toxin, the data obtained suggests that LAAO has the potential to stimulate apoptosis in HL-60 lines and HL-60. BCR-ABL and increase the effect of the inhibitor of protein kinase activity, MI, relevant data for future studies associated with the description of new drugs against chronic myeloid leukemia.
|
Page generated in 0.0503 seconds